Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
In the preceding three months, 15 analysts have released ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), presenting a wide array of perspectives from bullish to bearish.The table below offers a conden
BenzingaMay 2 10:00 ET
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanksMay 2 06:35 ET
Express News | Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $222 Price Target
BenzingaMay 2 06:35 ET
Jazz Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 107.09% Needham → $222 Reiterates Buy → Buy 04/10/2024 67.91% Cantor Fitzgerald → $180 Reiterat
BenzingaMay 2 06:33 ET
Optimistic Outlook for Jazz Pharmaceuticals Despite Q1 Challenges
TipRanksMay 2 06:31 ET
Buy Rating Affirmed: Jazz Pharmaceuticals' Resilient Base and Promising Pipeline Drive Positive Outlook
TipRanksMay 2 06:09 ET
Express News | Jazz Pharmaceuticals PLC : BofA Global Research Cuts Price Objective to $172 From $173
ReutersMay 2 06:04 ET
Earnings Call Summary | Jazz Pharmaceuticals(JAZZ.US) Q1 2024 Earnings Conference
The following is a summary of the Jazz Pharmaceuticals Plc (JAZZ) Q1 2024 Earnings Call Transcript:Financial Performance:Jazz Pharmaceuticals reported a total revenue of over $900 million across its p
moomoo AIMay 2 04:16 ET · Conference Call
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook
Jazz Pharmaceuticals (JAZZ) reported Q1 adjusted earnings late Wednesday of $2.68 per diluted share, down from $3.95 a year earlier. Analysts polled by Capital IQ expected $4.18. Revenue for the quart
MT NewswiresMay 2 03:53 ET
Express News | Jazz Pharmaceuticals PLC : TD Cowen Cuts Target Price to $200 From $225
ReutersMay 2 02:33 ET
Express News | Jazz Pharmaceuticals PLC: Affirmed Guidance for 2024
ReutersMay 1 17:46 ET
Express News | Jazz Pharmaceuticals Affirms 2024 Revenue Guidance $4B-$4.2B
BenzingaMay 1 17:08 ET
Jazz Pharmaceuticals Misses Top-line and Bottom-line Estimates; Reaffirms FY24 Outlook
Seeking AlphaMay 1 16:23 ET
GUIDANCE: (JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35
04:15 PM EDT, 05/01/2024 (MT Newswires) -- GUIDANCE: (JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35
MT NewswiresMay 1 16:15 ET
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care...
PR NewswireMay 1 16:10 ET
Express News | Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
ReutersMay 1 16:05 ET
Express News | Jazz Pharmaceuticals Q1 Adjusted EPS USD 2.68 Vs. Ibes Estimate USD 4.18
ReutersMay 1 16:05 ET
Express News | Jazz Pharmaceuticals Q1 EPS USD -0.23
ReutersMay 1 16:05 ET
Express News | Jazz Pharmaceuticals Q1 Net Income USD -14.618 Million
ReutersMay 1 16:05 ET
Express News | Jazz Pharmaceuticals Q1 Revenue USD 901.983 Million Vs. Ibes Estimate USD 953.9 Million
ReutersMay 1 16:05 ET
No Data
No Data